The participants looked into known strategies to delay CKD progression and improve cardiovascular prognosis, such as lifestyle interventions, blood pressure control, RAAS inhibition, SGLT2 inhibition, and mineralocorticoid receptor antagonists, and reviewed their role for different etiologies of kidney disease such as lupus nephritis, small vessel vasculitis, IgA nephropathy (IgAN), autosomal dominant polycystic kidney disease (ADPKD), Alport syndrome, and kidney amyloidosis. The gene discussed is SLC5A2; the disease is autosomal dominant polycystic kidney disease.